More on LGVN
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.50 |
|
|||
| Open | $0.51 | ||||
| 52 Wk High | $1.62 | ||||
| 52 Wk Low | $0.35 | ||||
| Day High | $0.51 | ||||
| Day Low | $0.48 | ||||
| P/E | N/A | ||||
| EPS | $-0.17 | ||||
| Volume | 230,994 | ||||
- Form PRE 14A Longeveron Inc. For: Mar 03
- Longeveron publishes Phase 2b stem cell trial results in Cell Stem Cell
- Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell
- Form 8-K Longeveron Inc. For: Feb 09
- Longeveron appoints Stephen Willard as CEO
- Longeveron® Appoints Stephen H. Willard as Chief Executive Officer
- Form SCHEDULE 13G/A Longeveron Inc. Filed by: Lincoln Alternative Strategies LLC
- Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
- Longeveron receives Japan patent for stem cell potency testing methods
- Longeveron® Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs)
Entities mentioned with LGVN
- FDA | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- H.C. Wainwright | View Related Stories »
- IPO | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
